In a large population of people with type 1 diabetes, the glycaemic target might not be achieved despite insulin therapy and issues around recurrent severe hypoglycaemia caused by insulin excess can result in irreversible neurological damage or even death.1 Clinical trials with allogeneic2 and terminally differentiated autologous3,4 stem cell-derived islets have provided convincing evidence that such therapies can restore durable normoglycaemic islet function in people with type 1 and type 2 diabetes.
In a large population of people with type 1 diabetes, the glycaemic target might not be achieved despite insulin therapy and issues around recurrent severe hypoglycaemia caused by insulin excess can result in irreversible neurological damage or even death.1 Clinical trials with allogeneic2 and terminally differentiated autologous3,4 stem cell-derived islets have provided convincing evidence that such therapies can restore durable normoglycaemic islet function in people with type 1 and type 2 diabetes.